Pharmabiz1d
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease
In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring ...
Le Lézard3d
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization ...
Mena FN3d
CHMP Issues Positive Recommendation For Approval Of Lecanemab In The EU
In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
GEN11d
Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Nasdaq17d
Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease
On the ADCS MCI-ADL, 51% of patients showed improvement or no decline and 48% showed improvement. These results – from no tau/low tau population and low amyloid populations – suggest that ...
Le Lézard17d
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
BioArctic AB's (publ) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, ...
Morningstar17d
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
These data show that 46% of patients improved or had no decline, and 33% showed improvement from baseline on the CDR-SB, with similar results for ADAS-Cog14 and on the ADCS MCI-ADL scales.
pharmaphorum10d
Eisai's full lecanemab phase 3 trial results for Alzheimer's presented at CTAD
Lecanemab also slowed decline of activities of daily living by 37% on ADCS MCI-ADL at the same time point. Adverse events in the lecanemab group were reported to have most commonly been infusion ...
pharmaphorum5d
After EU setback, Eisai/Biogen build case for Leqembi
with a similar pattern for the ADAS-Cog14 and ADCS MCI-ADL scales. That makes the case to start treatment as early as possible, said Eisai and Biogen. Both Leqembi and Kisunla have experimental ...
The Times of Israel3d
Trump’s AG pick called ADL ‘racist,’ invited Holocaust denier to State of the Union
JTA — US President-elect Donald Trump has chosen Matt Gaetz as his nominee for attorney general, putting forward a firebrand who has tussled with Jewish groups, embraced an antisemitic ...